Latest Market Capitalization News

Almonty Industries has announced a $700 million convertible senior notes offering due 2031, aiming to refinance existing debt and fund corporate initiatives amid rising tungsten demand.

Almonty Industries is set to join the prestigious Russell 1000 and 3000 indexes in June 2026, marking a significant milestone that highlights its growth and operational progress amid rising tungsten demand.

VRX Silica’s updated 2026 Bankable Feasibility Study for Arrowsmith North confirms robust economics with an ungeared NPV8 of A$179.2 million and binding offtake contracts securing nearly 1 million tonnes annually.

Electro Optic Systems (ASX:EOS) has closed its three-year turnaround and is now poised for growth, backed by a landmark high-energy laser contract, a major European acquisition, and a $175 million capital raise.

Brightstar Resources has secured full funding for its Goldfields Project, targeting 75,000oz gold production annually from mid-2027, while advancing the Sandstone Project towards a potential Tier-1 development with production aimed for 2029.

Genesis Minerals has reported a 29% jump in gold resources to 18.9 million ounces and a 19% rise in reserves to 4.4 million ounces as of December 2025, underpinning its ASPIRE 500 growth strategy with new assets and exploration boosts.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.

BlinkLab has completed onboarding all clinical sites for its pivotal FDA autism trial, enrolled the first participant, and launched a nationwide autism screening program in Morocco. A recent A$17.7 million capital raise will fund further trials and expansion into ADHD diagnostics.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

NEXTDC has priced and allocated a A$750 million subordinated wholesale notes offer at a floating rate of 3-month BBSW plus 350 basis points, enhancing its liquidity position amid an ambitious A$2.2 billion capital plan.

Auric Mining outlines a bold growth plan centered on Kalgoorlie, targeting 25,000–30,000 ounces of gold production from 2028 with a new processing facility and multiple project acquisitions.